Literature DB >> 31566580

IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption.

Victoria Langer1, Eugenia Vivi1, Daniela Regensburger1, Thomas H Winkler2, Maximilian J Waldner3, Timo Rath3, Benjamin Schmid4, Lisa Skottke1, Somin Lee5, Noo Li Jeon5, Thomas Wohlfahrt6, Viktoria Kramer3, Philipp Tripal4, Michael Schumann7, Stephan Kersting8, Claudia Handtrack8, Carol I Geppert9, Karina Suchowski10, Ralf H Adams11, Christoph Becker3, Andreas Ramming6, Elisabeth Naschberger1, Nathalie Britzen-Laurent1, Michael Stürzl1.   

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with rising incidence. Diseased tissues are heavily vascularized. Surprisingly, the pathogenic impact of the vasculature in IBD and the underlying regulatory mechanisms remain largely unknown. IFN-γ is a major cytokine in IBD pathogenesis, but in the context of the disease, it is almost exclusively its immune-modulatory and epithelial cell-directed functions that have been considered. Recent studies by our group demonstrated that IFN-γ also exerts potent effects on blood vessels. Based on these considerations, we analyzed the vessel-directed pathogenic functions of IFN-γ and found that it drives IBD pathogenesis through vascular barrier disruption. Specifically, we show that inhibition of the IFN-γ response in vessels by endothelial-specific knockout of IFN-γ receptor 2 ameliorates experimentally induced colitis in mice. IFN-γ acts pathogenic by causing a breakdown of the vascular barrier through disruption of the adherens junction protein VE-cadherin. Notably, intestinal vascular barrier dysfunction was also confirmed in human IBD patients, supporting the clinical relevance of our findings. Treatment with imatinib restored VE-cadherin/adherens junctions, inhibited vascular permeability, and significantly reduced colonic inflammation in experimental colitis. Our findings inaugurate the pathogenic impact of IFN-γ-mediated intestinal vessel activation in IBD and open new avenues for vascular-directed treatment of this disease.

Entities:  

Keywords:  Cytokines; Gastroenterology; Inflammatory bowel disease; Vascular Biology; endothelial cells

Mesh:

Substances:

Year:  2019        PMID: 31566580      PMCID: PMC6819119          DOI: 10.1172/JCI124884

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  83 in total

1.  Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis.

Authors:  Sven Flemming; Natalie Burkard; Melanie Renschler; Franziska Vielmuth; Michael Meir; Martin Alexander Schick; Christian Wunder; Christoph-Thomas Germer; Volker Spindler; Jens Waschke; Nicolas Schlegel
Journal:  Cardiovasc Res       Date:  2015-05-14       Impact factor: 10.787

Review 2.  Intestinal epithelial cells: regulators of barrier function and immune homeostasis.

Authors:  Lance W Peterson; David Artis
Journal:  Nat Rev Immunol       Date:  2014-03       Impact factor: 53.106

3.  Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo.

Authors:  M Corada; M Mariotti; G Thurston; K Smith; R Kunkel; M Brockhaus; M G Lampugnani; I Martin-Padura; A Stoppacciaro; L Ruco; D M McDonald; P A Ward; E Dejana
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

Review 4.  The role of adherens junctions and VE-cadherin in the control of vascular permeability.

Authors:  Elisabetta Dejana; Fabrizio Orsenigo; Maria Grazia Lampugnani
Journal:  J Cell Sci       Date:  2008-07-01       Impact factor: 5.285

5.  Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy.

Authors:  Elisabeth Naschberger; Roland S Croner; Susanne Merkel; Arno Dimmler; Philipp Tripal; Kerstin U Amann; Elisabeth Kremmer; Wolfgang M Brueckl; Thomas Papadopoulos; Christine Hohenadl; Werner Hohenberger; Michael Stürzl
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

6.  A gut-vascular barrier controls the systemic dissemination of bacteria.

Authors:  Ilaria Spadoni; Elena Zagato; Alice Bertocchi; Roberta Paolinelli; Edina Hot; Antonio Di Sabatino; Flavio Caprioli; Luca Bottiglieri; Amanda Oldani; Giuseppe Viale; Giuseppe Penna; Elisabetta Dejana; Maria Rescigno
Journal:  Science       Date:  2015-11-13       Impact factor: 47.728

7.  Vascular endothelial cadherin expression in lung specimens of patients with sepsis-induced acute respiratory distress syndrome and endothelial cell cultures.

Authors:  Martina C Herwig; Michael Tsokos; M Iris Hermanns; C James Kirkpatrick; Annette M Müller
Journal:  Pathobiology       Date:  2013-04-27       Impact factor: 4.342

8.  Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF.

Authors:  Ganna Tolstanova; Tetyana Khomenko; Xiaoming Deng; Longchuan Chen; Andrzej Tarnawski; Amrita Ahluwalia; Sandor Szabo; Zsuzsanna Sandor
Journal:  J Pharmacol Exp Ther       Date:  2008-12-05       Impact factor: 4.030

Review 9.  Endothelial cell-cell adhesion and signaling.

Authors:  Camilla Cerutti; Anne J Ridley
Journal:  Exp Cell Res       Date:  2017-06-08       Impact factor: 3.905

10.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  33 in total

1.  Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.

Authors:  Adrienne M Luoma; Shengbao Suo; Hannah L Williams; Tatyana Sharova; Keri Sullivan; Michael Manos; Peter Bowling; F Stephen Hodi; Osama Rahma; Ryan J Sullivan; Genevieve M Boland; Jonathan A Nowak; Stephanie K Dougan; Michael Dougan; Guo-Cheng Yuan; Kai W Wucherpfennig
Journal:  Cell       Date:  2020-06-29       Impact factor: 41.582

2.  Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease Extension.

Authors:  Carmen Argmann; Minami Tokuyama; Ryan C Ungaro; Ruiqi Huang; Ruixue Hou; Sakteesh Gurunathan; Roman Kosoy; Antonio Di'Narzo; Wenhui Wang; Bojan Losic; Haritz Irizar; Lauren Peters; Aleksandar Stojmirovic; Gabrielle Wei; Phillip H Comella; Mark Curran; Carrie Brodmerkel; Joshua R Friedman; Ke Hao; Eric E Schadt; Jun Zhu; Judy Cho; Noam Harpaz; Marla C Dubinsky; Bruce E Sands; Andrew Kasarskis; Saurabh Mehandru; Jean-Frederic Colombel; Mayte Suárez-Fariñas
Journal:  Gastroenterology       Date:  2021-09-02       Impact factor: 22.682

3.  Chronic Toxoplasma gondii infection enhances susceptibility to colitis.

Authors:  Iti Saraav; Luisa Cervantes-Barragan; Philipp Olias; Yong Fu; Qiuling Wang; Leran Wang; Yi Wang; Matthias Mack; Megan T Baldridge; Thaddeus Stappenbeck; Marco Colonna; L David Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-07       Impact factor: 11.205

4.  Single-cell transcriptomic profiling of lung endothelial cells identifies dynamic inflammatory and regenerative subpopulations.

Authors:  Lianghui Zhang; Shang Gao; Zachary White; Yang Dai; Asrar B Malik; Jalees Rehman
Journal:  JCI Insight       Date:  2022-06-08

Review 5.  Gut microbiome and autoimmune disorders.

Authors:  Walaa Abdelaty Shaheen; Mohammed Nabil Quraishi; Tariq H Iqbal
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

Review 6.  Bioengineered Co-culture of organoids to recapitulate host-microbe interactions.

Authors:  Min Beom Kim; Soonho Hwangbo; Sungho Jang; Yun Kee Jo
Journal:  Mater Today Bio       Date:  2022-07-01

7.  IFNγ-Treated Macrophages Induce EMT through the WNT Pathway: Relevance in Crohn's Disease.

Authors:  Dulce C Macias-Ceja; Sandra Coll; Cristina Bauset; Marta Seco-Cervera; Laura Gisbert-Ferrándiz; Francisco Navarro; Jesus Cosin-Roger; Sara Calatayud; María D Barrachina; Dolores Ortiz-Masia
Journal:  Biomedicines       Date:  2022-05-08

8.  Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis.

Authors:  Justine Maller; Emily Fox; K T Park; Sarah Sertial Paul; Kevin Baszis; Charlotte Borocco; Sampath Prahalad; Pierre Quartier; Adam Reinhardt; Dieneke Schonenberg-Meinema; Lauren Shipman-Duensing; Maria Teresa Terreri; Julia Simard; Idit Lavi; Elizabeth Chalom; Joyce Hsu; Devy Zisman; Elizabeth D Mellins
Journal:  J Rheumatol       Date:  2020-06-15       Impact factor: 4.666

9.  Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.

Authors:  Jurjan Aman; Erik Duijvelaar; Liza Botros; Azar Kianzad; Job R Schippers; Patrick J Smeele; Sara Azhang; Imke H Bartelink; Ahmed A Bayoumy; Pierre M Bet; Wim Boersma; Peter I Bonta; Karin A T Boomars; Lieuwe D J Bos; Job J M H van Bragt; Gert-Jan Braunstahl; Lucas R Celant; Katrien A B Eger; J J Miranda Geelhoed; Yurika L E van Glabbeek; Hans P Grotjohan; Laura A Hagens; Chris M Happe; Boaz D Hazes; Leo M A Heunks; Michel van den Heuvel; Wouter Hoefsloot; Rianne J A Hoek; Romke Hoekstra; Herman M A Hofstee; Nicole P Juffermans; E Marleen Kemper; Renate Kos; Peter W A Kunst; Ariana Lammers; Ivo van der Lee; E Laurien van der Lee; Anke-Hilse Maitland-van der Zee; Pearl F M Mau Asam; Adinda Mieras; Mirte Muller; Liesbeth Neefjes; Esther J Nossent; Laurien M A Oswald; Maria J Overbeek; Carolina Pamplona; Nienke Paternotte; Niels Pronk; Michiel A de Raaf; Bas F M van Raaij; Merlijn Reijrink; Marcus J Schultz; Ary Serpa Neto; Elise M Slob; Frank W J M Smeenk; Marry R Smit; A Josien Smits; Janneke E Stalenhoef; Pieter R Tuinman; Arthur L E M Vanhove; Jessie N Wessels; Jessie C C van Wezenbeek; Anton Vonk Noordegraaf; Frances S de Man; Harm J Bogaard
Journal:  Lancet Respir Med       Date:  2021-06-17       Impact factor: 30.700

Review 10.  Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.

Authors:  Wan Sun; Richard A Lirio; Jennifer Schneider; Jiri Aubrecht; Harisha Kadali; Mike Baratta; Parul Gulati; Ajit Suri; Tiffany Lin; Raghavan Vasudevan; Maria Rosario
Journal:  Clin Pharmacol Drug Dev       Date:  2020-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.